Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May

TransMedics (TMDX), Everus (ECG), and Excelerate Energy (EE) reported significant sales beats in their recent earnings releases, leading to notable stock price increases. TransMedics' Q1 2025 sales exceeded expectations by 16%, driving a nearly 20% share price increase, while Everus' Q1 revenue beat estimates by over 22% due to data center demand, resulting in a 17% stock jump and increased analyst price targets. Excelerate Energy's Q1 sales surpassed forecasts by over 51% amid rising global LNG demand, although concerns exist regarding potential oversupply in the LNG market by 2030.

Analysis

Three mid-cap companies, TransMedics Group (TMDX), Everus (ECG), and Excelerate Energy (EE), reported substantial sales outperformance in their May earnings releases, underscoring the potential for significant earnings surprises in less-covered market segments. TransMedics, a healthcare firm, announced Q1 2025 sales of $143 million, a 16% beat against analyst consensus, driving 48% year-over-year revenue growth and adjusted EPS of $0.70, more than double expectations; the company also raised its full-year revenue guidance midpoint by $34 million to $575 million, implying 30% growth for 2025 compared to 2024. Despite a near 20% share price increase post-earnings, TMDX shares remained approximately 20% below their August 2024 peak as of June 10, reflecting a history of stock volatility including a 30% drop after a Q3 2024 earnings miss. Everus, a construction services company, posted Q1 revenue of nearly $827 million, exceeding forecasts by over 22% (a $150 million beat) and delivering 32% sales growth, significantly above the anticipated 8%. This resulted in a 31% rise in non-adjusted EPS to $0.72, contrary to analyst expectations of a decline, and a 17% share price increase. Notably, Everus's order backlog surged 41% to $3.1 billion, with its Electrical and Mechanical segment backlog growing 46% fueled by data center construction, providing strong revenue visibility and prompting price target increases from analysts like Stifel Nicolaus and DA Davidson. Excelerate Energy, operating in the LNG sector, reported Q1 sales of $315 million, a striking 51% above estimates of $208 million, with revenues growing 57% compared to expectations of 4% growth, leading to a 10% share price rise. While Jefferies initiated coverage with a positive outlook citing rising global LNG demand and future contract potential, a long-term concern exists regarding potential LNG supply significantly outstripping demand by 2030, which could put downward pressure on prices and impact Excelerate's investment thesis.

Key Decisions for Investors

• Investors should recognize that mid-cap stocks, often experiencing lighter analyst coverage, can present notable upside during earnings season, as exemplified by the significant sales beats and subsequent share price movements of TMDX, ECG, and EE.
• For TransMedics (TMDX), the robust Q1 2025 performance and increased full-year guidance are positive indicators, yet its historical share price volatility and current discount from its all-time high warrant careful consideration of risk tolerance.
• Everus (ECG) demonstrates strong fundamental tailwinds with its substantial 41% order backlog growth, particularly in the data center-driven Electrical and Mechanical segment, suggesting a solid foundation for sustained revenue growth and potential for continued share appreciation.
• Excelerate Energy (EE) offers exposure to current favorable LNG market conditions and positive near-term analyst sentiment, but investors should diligently monitor long-term LNG supply and demand dynamics, as a potential future oversupply could challenge the company's growth trajectory and contract valuations.